A Randomised, Double-Blind, Vehicle-Controlled Study of the Safety and Tolerability of Two Dosage Forms of BTX 1702 in Patients with Papulopustular Rosacea
Latest Information Update: 21 May 2021
Price :
$35 *
At a glance
- Drugs Cannabidiol (Primary)
- Indications Rosacea
- Focus Adverse reactions
- Sponsors Botanix Pharmaceuticals
- 17 May 2021 Status changed from not yet recruiting to withdrawn prior to enrolment. Reason: Study was not commenced.
- 23 Apr 2020 Planned initiation date changed from 28 Feb 2020 to 1 Jul 2020.
- 20 Feb 2020 New trial record